Literature DB >> 12789543

Chemotactic and chemokinetic properties of topical ophthalmic preparations.

Pinar Cakar Ozdal1, Jean Deschênes, Marcello Rudzinski, Emilia Antecka, Malcolm G Baines.   

Abstract

PURPOSE: Chronic ocular inflammation can be due to a disease process or to iatrogenic factors that attract inflammatory cells to the anterior chamber. This study was conducted to investigate the effect of commonly used ophthalmic preparations on leukocyte migration.
METHODS: A modified multi-well Boyden chamber was used to study the chemotactic and chemokinetic effects of 33 commercial ophthalmic preparations. To determine whether the chemotactic effect was a property of the commercial ophthalmic preparation or other chemicals present in the products, experiments were also done with some common preservatives and excipients.
RESULTS: Of the drugs, 14 (42.4%) showed chemokinetic and/or chemotactic activity and 19 (57.6%) had either no effect or decreased neutrophil migration. Of the preservatives and excipients, 5 (62.5%) were found to be chemotactic. Eleven of 14 chemotactic drugs (78.6%) and 8 of 19 non-chemotactic drugs (42.1%) were positive for at least one chemotactic excipient. The correlation between chemotactic ophthalmic preparations and the presence of a chemotactic excipient in their composition was significant (p < 0.05).
CONCLUSIONS: Chemotactic activity was commonly found in commercial ophthalmic preparation. Furthermore, the presence of certain chemotactic preservatives and/or excipients was a contributing factor enhancing this property. Avoiding known chemotactic compounds or adjusting the intervals of the treatment may help to eliminate this iatrogenic component of the inflammatory process especially in patients with chronic ocular inflammation.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12789543     DOI: 10.1076/ceyr.25.6.363.14232

Source DB:  PubMed          Journal:  Curr Eye Res        ISSN: 0271-3683            Impact factor:   2.424


  2 in total

1.  Increased SPARC expression in primary angle closure glaucoma iris.

Authors:  Jocelyn Chua; Li Fong Seet; Yuzhen Jiang; Roseline Su; Hla Myint Htoon; Amanda Charlton; Tin Aung; Tina T Wong
Journal:  Mol Vis       Date:  2008-10-20       Impact factor: 2.367

2.  The chemotactic properties of various topical brimonidine tartrate ophthalmic preparations.

Authors:  Ruiz Simonato Alonso; Helena Parente Solari; Eduardo de França Damasceno; Miguel Noel Nascentes Burnier; Marcelo Palis Ventura
Journal:  BMC Pharmacol Toxicol       Date:  2020-03-23       Impact factor: 2.483

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.